In June 2022, Prof. McNally presented the 12 month RECOVER data from the 12+ patients at the ECFS Conference in Rotterdam. This data showed that ELX/TEZ/IVA is associated with significant and sustained improvements in an array of outcome measures in people with CF. A significant proportion (40%) of people in the homozygous deltaF508 group had a sweat chloride in the normal range on treatment. Data collection is continuing for RECOVER and we hope to present more findings and study updates at future conferences.